-
1
-
-
33751530274
-
Steroid receptors and their role in the biology and control of breast cancer growth
-
Cordera F, Jordan VC. Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol 2006; 33: 631-641.
-
(2006)
Semin Oncol
, vol.33
, pp. 631-641
-
-
Cordera, F.1
Jordan, V.C.2
-
2
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
3
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
4
-
-
33847136743
-
Triple-negative breast cancer: Therapeutic options
-
Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-244.
-
(2007)
Lancet Oncol
, vol.8
, pp. 235-244
-
-
Cleator, S.1
Heller, W.2
Coombes, R.C.3
-
5
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou CM, Sorlie T, Elsen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Elsen, M.B.3
-
6
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 10869-10874
-
-
Sorlie, T.1
Perou, C.M.2
Tibshirani, R.3
-
7
-
-
0042838307
-
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
-
Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 10393-10398
-
-
Sotiriou, C.1
Neo, S.Y.2
McShane, L.M.3
-
8
-
-
0038386613
-
Src family kinases in tumor progression and metastasis
-
Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-358.
-
(2003)
Cancer Metastasis Rev
, vol.22
, pp. 337-358
-
-
Summy, J.M.1
Gallick, G.E.2
-
9
-
-
2942618768
-
A renaissance for SRC
-
Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4: 470-480.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 470-480
-
-
Yeatman, T.J.1
-
10
-
-
0000374583
-
Overexpression of the c-SRC protein does not induce transformation of NH3T3 cells
-
Shalloway D, Coussens PM, Yacíuk P. Overexpression of the c-SRC protein does not induce transformation of NH3T3 cells. Proc Natl Acad Sci USA 1984; 81: 7071-7075.
-
(1984)
Proc Natl Acad Sci USA
, vol.81
, pp. 7071-7075
-
-
Shalloway, D.1
Coussens, P.M.2
Yacíuk, P.3
-
11
-
-
0031439247
-
Cellular functions regulated by Src family kinases
-
Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13: 513-609.
-
(1997)
Annu Rev Cell Dev Biol
, vol.13
, pp. 513-609
-
-
Thomas, S.M.1
Brugge, J.S.2
-
12
-
-
17444374230
-
Src kinase regulation by phosphorylation and dephosphorylation
-
Roskoski R Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005; 331: 1-14.
-
(2005)
Biochem Biophys Res Commun
, vol.331
, pp. 1-14
-
-
Roskoski Jr., R.1
-
13
-
-
34248397608
-
Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells
-
Chou MT, Wang J, Fujita DJ. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem 2002; 3: 32.
-
(2002)
BMC Biochem
, vol.3
, pp. 32
-
-
Chou, M.T.1
Wang, J.2
Fujita, D.J.3
-
14
-
-
0036241054
-
EphrinB phosphorylation and reverse signaling: Regulation by Src kinases and PTP-BL phosphatase
-
Palmer A, Zimmer M, Erdmann KS et al. EphrinB phosphorylation and reverse signaling: Regulation by Src kinases and PTP-BL phosphatase. Mol Cell 2002; 9: 725-737.
-
(2002)
Mol Cell
, vol.9
, pp. 725-737
-
-
Palmer, A.1
Zimmer, M.2
Erdmann, K.S.3
-
15
-
-
0020645860
-
Expression of pp60c-src protein Wase in adult and fetal human tissue: High activities in some sarcomas and mammary carcinomas
-
Jacobs C, Rubsamen H. Expression of pp60c-src protein Wase in adult and fetal human tissue: High activities in some sarcomas and mammary carcinomas. Cancer Res 1983; 43: 1696-1702.
-
(1983)
Cancer Res
, vol.43
, pp. 1696-1702
-
-
Jacobs, C.1
Rubsamen, H.2
-
16
-
-
0026674221
-
Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product
-
Ottenhoff-Kalff AE, Rijksen G, van Beurden EA et al. Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res 1992; 52: 4773-4778.
-
(1992)
Cancer Res
, vol.52
, pp. 4773-4778
-
-
Ottenhoff-Kalff, A.E.1
Rijksen, G.2
van Beurden, E.A.3
-
17
-
-
0031979414
-
Characterization of human epidermal growth factor receptor and c-Src interactions in human break tumor cells
-
Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c-Src interactions in human break tumor cells. Mol Carcinog 1998; 21: 261-272.
-
(1998)
Mol Carcinog
, vol.21
, pp. 261-272
-
-
Biscardi, J.S.1
Belsches, A.P.2
Parsons, S.J.3
-
18
-
-
0030474489
-
c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis
-
Verbeek BS, Vroom TM, Driaansen-Slot SS et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996; 180: 383-388.
-
(1996)
J Pathol
, vol.180
, pp. 383-388
-
-
Verbeek, B.S.1
Vroom, T.M.2
Driaansen-Slot, S.S.3
-
19
-
-
8344223854
-
Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: Implications for cell proliferation
-
Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: Implications for cell proliferation. Oncogene 2004; 23: 7979-7989.
-
(2004)
Oncogene
, vol.23
, pp. 7979-7989
-
-
Shupnik, M.A.1
-
20
-
-
24644510849
-
c-Src-null mice exhibit defects in normal mammary gland development and ER-alpha signalling
-
Kim H, Laing M, Muller W. c-Src-null mice exhibit defects in normal mammary gland development and ER-alpha signalling. Oncogene 2005; 24: 5629-5636.
-
(2005)
Oncogene
, vol.24
, pp. 5629-5636
-
-
Kim, H.1
Laing, M.2
Muller, W.3
-
21
-
-
3142511046
-
Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones
-
Boonyaratanakornkit V, Edwards DP. Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones. Essays Biochem 2004; 40: 105-120.
-
(2004)
Essays Biochem
, vol.40
, pp. 105-120
-
-
Boonyaratanakornkit, V.1
Edwards, D.P.2
-
22
-
-
33846235881
-
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells
-
Herynk MH, Beyer AR, Cui Y et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 2006; 5: 3023-3031.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 3023-3031
-
-
Herynk, M.H.1
Beyer, A.R.2
Cui, Y.3
-
23
-
-
33749316418
-
The epidermal growth factor receptor pathway: A model for targeted therapy
-
Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5268-5272
-
-
Scaltriti, M.1
Baselga, J.2
-
24
-
-
0029121267
-
Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers
-
Maa MC, Leu TH, McCarley DJ et al. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers. Proc Nat Acad Sci USA 1995; 92: 6981-6985.
-
(1995)
Proc Nat Acad Sci USA
, vol.92
, pp. 6981-6985
-
-
Maa, M.C.1
Leu, T.H.2
McCarley, D.J.3
-
25
-
-
0023675030
-
Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src
-
Luttrell DK, Luttrell LM, Parsons SJ. Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src. Mot Cell Biol 1988; 8: 497-501.
-
(1988)
Mot Cell Biol
, vol.8
, pp. 497-501
-
-
Luttrell, D.K.1
Luttrell, L.M.2
Parsons, S.J.3
-
26
-
-
0024478058
-
pp6oc-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src
-
Wilson LK, Luttrell DK, Parsons JT Parsons SJ. pp6oc-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol Cell Biol 1989; 9: 1636-1544.
-
(1989)
Mol Cell Biol
, vol.9
, pp. 1636-1544
-
-
Wilson, L.K.1
Luttrell, D.K.2
Parsons, J.T.3
Parsons, S.J.4
-
27
-
-
0035399133
-
An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway
-
Olayioye MA, Badache A, Daly JM, Hynes NE. An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway. Exp Cell Res 2001; 267: 81-87.
-
(2001)
Exp Cell Res
, vol.267
, pp. 81-87
-
-
Olayioye, M.A.1
Badache, A.2
Daly, J.M.3
Hynes, N.E.4
-
28
-
-
0033546315
-
ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases
-
Olayioye MA, Beuvink I, Horsch K et al. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999; 274: 17209-17218.
-
(1999)
J Biol Chem
, vol.274
, pp. 17209-17218
-
-
Olayioye, M.A.1
Beuvink, I.2
Horsch, K.3
-
29
-
-
0035799531
-
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
-
Garcia R, Bowman TL, Niu G et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20: 2499-2513.
-
(2001)
Oncogene
, vol.20
, pp. 2499-2513
-
-
Garcia, R.1
Bowman, T.L.2
Niu, G.3
-
30
-
-
33745402375
-
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells
-
Hiscox S, Morgan L, Green TP et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006; 97: 263-274.
-
(2006)
Breast Cancer Res Treat
, vol.97
, pp. 263-274
-
-
Hiscox, S.1
Morgan, L.2
Green, T.P.3
-
31
-
-
34249326610
-
c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function
-
Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 2007; 26: 3503-3510.
-
(2007)
Oncogene
, vol.26
, pp. 3503-3510
-
-
Ishizawar, R.C.1
Miyake, T.2
Parsons, S.J.3
-
32
-
-
0036674501
-
Dissemination and growth of cancer cells in metastatic sites
-
Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 563-572
-
-
Chambers, A.F.1
Groom, A.C.2
MacDonald, I.C.3
-
33
-
-
24644471128
-
c and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition
-
Avizienyte E, Frame MC, Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005; 17: 542-547.
-
(2005)
Curr Opin Cell Biol
, vol.17
, pp. 542-547
-
-
Avizienyte, E.1
Frame Sr, M.C.2
-
34
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
35
-
-
33645364706
-
Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) [abstract]
-
19s
-
Miller KD, Burstein HJ, Elias HID et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) [abstract]. J Clin Oncol 2005; 23: 19s.
-
(2005)
J Clin Oncol
, vol.23
-
-
Miller, K.D.1
Burstein, H.J.2
Elias, H.I.D.3
-
36
-
-
0029068339
-
Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
-
Mukhopadhyay D, Tsiokas L, Zhou XM et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995; 375: 577-581.
-
(1995)
Nature
, vol.375
, pp. 577-581
-
-
Mukhopadhyay, D.1
Tsiokas, L.2
Zhou, X.M.3
-
37
-
-
0035884402
-
Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF) expression in mammary carcinoma
-
Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF) expression in mammary carcinoma. Cancer Res 2001; 61: 6952-6957.
-
(2001)
Cancer Res
, vol.61
, pp. 6952-6957
-
-
Pal, S.1
Datta, K.2
Mukhopadhyay, D.3
-
38
-
-
33744936606
-
Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors
-
Tan M, Li P, Sun M et al. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene, 2006; 25: 3286-3295.
-
(2006)
Oncogene
, vol.25
, pp. 3286-3295
-
-
Tan, M.1
Li, P.2
Sun, M.3
-
39
-
-
33746342801
-
Role of c-Src in human MCF7 breast cancer cell tumorigenesis
-
Gonzalez L, Gullo-Ortuno MT, Garcia-Martinez JM et al. Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 2006; 281: 20851-20864.
-
(2006)
J Biol Chem
, vol.281
, pp. 20851-20864
-
-
Gonzalez, L.1
Gullo-Ortuno, M.T.2
Garcia-Martinez, J.M.3
-
40
-
-
0034686024
-
Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells
-
Gutwein P, Oleszewski M, Mechtersheimer S et al. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 2000; 275: 15490-15497.
-
(2000)
J Biol Chem
, vol.275
, pp. 15490-15497
-
-
Gutwein, P.1
Oleszewski, M.2
Mechtersheimer, S.3
-
41
-
-
31544460437
-
Activation of stat3 in primary tumors f rorn high-risk breast cancer patients is associated with elevated levels at activated SRC and survivin expression
-
Diaz N, Minton S, Cox C et al. Activation of stat3 in primary tumors f rorn high-risk breast cancer patients is associated with elevated levels at activated SRC and survivin expression. Clin Cancer Res 2006; 12: 20-28.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 20-28
-
-
Diaz, N.1
Minton, S.2
Cox, C.3
-
42
-
-
0026023289
-
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
-
Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
-
(1991)
Cell
, vol.64
, pp. 693-702
-
-
Soriano, P.1
Montgomery, C.2
Geske, R.3
Bradley, A.4
-
43
-
-
0026612467
-
Requirement at pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice
-
Boyce BF, Yoneda T, Lowe C et al. Requirement at pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90: 1622-1627.
-
(1992)
J Clin Invest
, vol.90
, pp. 1622-1627
-
-
Boyce, B.F.1
Yoneda, T.2
Lowe, C.3
-
44
-
-
0035825121
-
Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility
-
Sanjay A, Houghton A, Neff L et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 2001; 152: 181-195.
-
(2001)
J Cell Biol
, vol.152
, pp. 181-195
-
-
Sanjay, A.1
Houghton, A.2
Neff, L.3
-
45
-
-
0041513490
-
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis
-
Myoui A, Nishimura R, Williams PJ et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003; 63: 5028-5033.
-
(2003)
Cancer Res
, vol.63
, pp. 5028-5033
-
-
Myoui, A.1
Nishimura, R.2
Williams, P.J.3
-
46
-
-
0028333974
-
Parathyroid hormone-related peptide is a downstream target for ras and src activation
-
Li X, Drucker DJ. Parathyroid hormone-related peptide is a downstream target for ras and src activation. J Biol Chem 1994; 269: 6263-6266.
-
(1994)
J Biol Chem
, vol.269
, pp. 6263-6266
-
-
Li, X.1
Drucker, D.J.2
-
47
-
-
0034676060
-
Decreased c-Src: Expression enhances osteololast differentiation and bone formation
-
Marzia M, Sims NA, Voït S et al. Decreased c-Src: Expression enhances osteololast differentiation and bone formation. J Cell Biol 2000; 151: 311-320.
-
(2000)
J Cell Biol
, vol.151
, pp. 311-320
-
-
Marzia, M.1
Sims, N.A.2
Voït, S.3
-
48
-
-
17344380187
-
A Src SH2 selective binding compound inhibits osteoclast-mediated resorption
-
Violette SM, Shakespeare WC, Bartlett C et al. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. Chem Biol 2000; 7: 225-235.
-
(2000)
Chem Biol
, vol.7
, pp. 225-235
-
-
Violette, S.M.1
Shakespeare, W.C.2
Bartlett, C.3
-
49
-
-
33744813556
-
Genes associated with breast cancer metastatic to bone
-
Smid M, Wang Y, Klijn JG et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006; 24: 2261-2267.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2261-2267
-
-
Smid, M.1
Wang, Y.2
Klijn, J.G.3
-
50
-
-
0038488950
-
A multigenic program mediating breast cancer metastasis to bone
-
Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549.
-
(2003)
Cancer Cell
, vol.3
, pp. 537-549
-
-
Kang, Y.1
Siegel, P.M.2
Shu, W.3
-
51
-
-
25144517586
-
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab
-
Mass RD, Press MF, Anderson S et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast, Cancer 2005; 6: 240-246.
-
(2005)
Clin Breast, Cancer
, vol.6
, pp. 240-246
-
-
Mass, R.D.1
Press, M.F.2
Anderson, S.3
-
53
-
-
33744960226
-
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
-
Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
-
(2006)
JAMA
, vol.295
, pp. 2492-2502
-
-
Carey, L.A.1
Perou, C.M.2
Livasy, C.A.3
-
54
-
-
34548701082
-
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ 'triple-negative' breast cancer cell lines growing in vitro
-
Finn IRS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ 'triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326.
-
(2007)
Breast Cancer Res Treat
, vol.105
, pp. 319-326
-
-
Finn, I.R.S.1
Dering, J.2
Ginther, C.3
-
55
-
-
33947225176
-
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
-
Huang F, Reeves K, Han K et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection. Cancer Res 2007; 67: 2226-2238.
-
(2007)
Cancer Res
, vol.67
, pp. 2226-2238
-
-
Huang, F.1
Reeves, K.2
Han, K.3
-
56
-
-
19944428353
-
Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2- methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
-
Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2- methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
-
(2004)
J Med Chem
, vol.47
, pp. 6658-6661
-
-
Lombardo, L.J.1
Lee, F.Y.2
Chen, P.3
-
57
-
-
26444468152
-
Dasatinib (BMS-3548285) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoplosis of head and neck squamous cell carcinoma and non-small cell lung cancer cell
-
Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-3548285) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoplosis of head and neck squamous cell carcinoma and non-small cell lung cancer cell. Clin Cancer Res 2005, 11: 6924-6932.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6924-6932
-
-
Johnson, F.M.1
Saigal, B.2
Talpaz, M.3
Donato, N.J.4
-
58
-
-
33745243692
-
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
-
Song L, Morris M, Bagui T et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006; 66: 5542-5548.
-
(2006)
Cancer Res
, vol.66
, pp. 5542-5548
-
-
Song, L.1
Morris, M.2
Bagui, T.3
-
59
-
-
33644647192
-
Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
-
Trevino A Summy JM, Lesslie DP et al. Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006; 168: 962-972.
-
(2006)
Am J Pathol
, vol.168
, pp. 962-972
-
-
Trevino, A.1
Summy, J.M.2
Lesslie, D.P.3
-
60
-
-
29144492198
-
BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo [abstract]
-
Lee FY, Lombardo L, Camuso A et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo [abstract]. Proc Am Assoc Cancer Res 2005; 46: 159.
-
(2005)
Proc Am Assoc Cancer Res
, vol.46
, pp. 159
-
-
Lee, F.Y.1
Lombardo, L.2
Camuso, A.3
-
61
-
-
33846226773
-
Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003) [abstract]
-
132s
-
Luo FR, Barrett Y, Ji P et al. Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003) [abstract]. J Clin Oncol 2006; 24: 132s.
-
(2006)
J Clin Oncol
, vol.24
-
-
Luo, F.R.1
Barrett, Y.2
Ji, P.3
-
62
-
-
33847728182
-
A Src/Abl kinase Inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo
-
Jallal H, Valentino ML, Chen G et al. A Src/Abl kinase Inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67: 1580-1588.
-
(2007)
Cancer Res
, vol.67
, pp. 1580-1588
-
-
Jallal, H.1
Valentino, M.L.2
Chen, G.3
-
63
-
-
20444500171
-
SKJ-606, a Src/AbI inhibitor with in vivo activity in colon tumor xenograft models
-
Golas A Lucas J, Etienne C et al. SKJ-606, a Src/AbI inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005; 65: 5358-5364.
-
(2005)
Cancer Res
, vol.65
, pp. 5358-5364
-
-
Golas, A.1
Lucas, J.2
Etienne, C.3
-
64
-
-
48749101362
-
-
Hennequin LF, Allen J, Breed J et al
-
Hennequin LF, Allen J, Breed J et al.
-
-
-
-
65
-
-
34249776956
-
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells
-
Hiscox S, Jordan NJ, Morgan L et al. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 2007; 24: 157-167.
-
(2007)
Clin Exp Metastasis
, vol.24
, pp. 157-167
-
-
Hiscox, S.1
Jordan, N.J.2
Morgan, L.3
-
66
-
-
33745928222
-
The effect of AZD0530, a highly selective, orally available SrclAbl kinase inhibitor, on biomarkers of bone resorption in healthy males [abstract]
-
202s
-
Eastell R, Hannon RA, Gallagher N et al. The effect of AZD0530, a highly selective, orally available SrclAbl kinase inhibitor, on biomarkers of bone resorption in healthy males [abstract]. J Clin Oncol 2005; 23: 202s.
-
(2005)
J Clin Oncol
, vol.23
-
-
Eastell, R.1
Hannon, R.A.2
Gallagher, N.3
-
67
-
-
29144523093
-
Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor [abstract]
-
223s
-
Lockton A Smethurst D, Macpherson M et al. Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor [abstract]. J Clin Oncol 2005; 23: 223s.
-
(2005)
J Clin Oncol
, vol.23
-
-
Lockton, A.1
Smethurst, D.2
Macpherson, M.3
-
68
-
-
29144435297
-
Inhibition of osteoclastic bone resorption by the novel, potent, and selective c-Src/Abl kinase inhibitor, AZD0530 [abstract)
-
Mullender MG, Everts V, Green TP. Inhibition of osteoclastic bone resorption by the novel, potent, and selective c-Src/Abl kinase inhibitor, AZD0530 [abstract). Proc Am Assoc Cancer Res 2005; 46: 686.
-
(2005)
Proc Am Assoc Cancer Res
, vol.46
, pp. 686
-
-
Mullender, M.G.1
Everts, V.2
Green, T.P.3
-
69
-
-
34748881947
-
Next generation molecular targeted agents for breast cancer: Focus on EGFR and VEGFR pathways
-
Hitake K, Tokudome N, Ito Y. Next generation molecular targeted agents for breast cancer: Focus on EGFR and VEGFR pathways. Breast Cancer 2007; 14: 132-149.
-
(2007)
Breast Cancer
, vol.14
, pp. 132-149
-
-
Hitake, K.1
Tokudome, N.2
Ito, Y.3
-
70
-
-
0037234153
-
Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells
-
Boudny V, Nakano S. Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells. Anticancer Res 2003; 23: 7-12.
-
(2003)
Anticancer Res
, vol.23
, pp. 7-12
-
-
Boudny, V.1
Nakano, S.2
-
71
-
-
8544272554
-
Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-Induced apoptosis
-
Griffiths GJ, Koh MY, Brunton VG et al. Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-Induced apoptosis. J Biol Chem 2004; 279: 46113-46121.
-
(2004)
J Biol Chem
, vol.279
, pp. 46113-46121
-
-
Griffiths, G.J.1
Koh, M.Y.2
Brunton, V.G.3
|